scPharmaceuticals Inc.
scpharmaceuticals.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2025 10-Q, filed Aug 7, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Feb 11, 2026.
10-Q for Q2 FY2025, filed Aug 7, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Sells FUROSCIX, a subcutaneous treatment for fluid overload in adults with chronic heart failure and chronic kidney disease.
10-K for FY2024, filed Mar 19, 2025We are a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations while developing…View ↗
In May 2024, we submitted an supplemental New Drug Application (sNDA), seeking to expand the indication of FUROSCIX to include the…View ↗
FUROSCIX is our novel formulation of furosemide contained in a pre-filled, Crystal Zenith® cartridge and self- administered subcutaneously…View ↗
How Did They Make Money?
The company sells FUROSCIX to specialty pharmacies and specialty distributors, with sales counted when the customer receives the product.
10-K for FY2024, filed Mar 19, 2025FUROSCIX was approved by the FDA on October 7, 2022. The Company launched sales of FUROSCIX in the first quarter of 2023 and its customers…View ↗
$36.3M
-
10-K for FY2024, filed Mar 19, 2025
$36.3M ↗
Who Were Their Customers?
FUROSCIX is sold to specialty pharmacies and specialty distributors.
10-K for FY2024, filed Mar 19, 2025FUROSCIX was approved by the FDA on October 7, 2022. The Company launched sales of FUROSCIX in the first quarter of 2023 and its customers…View ↗
Did Revenues Turn Into Profits?
No. It lost $85.1M in FY2024.
10-K for FY2024, filed Mar 19, 2025
−$64.8MView ↗
10-K for FY2024, filed Mar 19, 2025
−$85.1MView ↗
10-K for FY2024, filed Mar 19, 2025
−$70.5MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2025, filed Aug 7, 2025
−$18MView ↗
- ▲ +5% (Loss)
- vs −$17.1M in Q2 FY2024
-
Oct 7, 2025
MannKind completed its acquisition of scPharmaceuticals
scPharmaceuticals became a direct wholly owned subsidiary of MannKind.
Sources
8-K, filed Oct 7, 2025
The Offer and related withdrawal rights expired as scheduled at one minute after 11:59 p.m., Eastern time, on October 6, 2025 (such date…View ↗
-
Aug 25, 2025
MannKind agreed to acquire scPharmaceuticals
The planned transaction involved a tender offer followed by a merger.
Sources
8-K, filed Aug 25, 2025
On August 24, 2025, scPharmaceuticals Inc., a Delaware corporation (the “Company” or “scPharmaceuticals”), entered into an Agreement and…View ↗
From candidate to marketed treatment
FUROSCIX was a product candidate being developed for worsening heart failure; it is now an approved, marketed treatment for heart failure, with an expanded chronic kidney disease indication.
10-K for FY2021, filed Mar 22, 2022 10-K for FY2024, filed Mar 19, 2025We are a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of…View ↗
Who Did They Compete With?
Competes with Abbott Laboratories, Amgen, AstraZeneca, Bayer, Bioheart, Boston Scientific, Corstasis, GlaxoSmithKline, Johnson & Johnson, Eli Lilly and, Merck &, Medtronic, Novartis, Pfizer, Roche, Sanofi, Sarfez Pharmaceuticals, Servier Pharmaceuticals, SQ Innovation, and Takeda Pharmaceutical
10-K for FY2024, filed Mar 19, 2025Our industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face…View ↗
Loading...
